On March 4th, 2019, Dr. Nghiem presented at the annual American Academy of Dermatology (AAD) conference on the need to prioritize treatment modalities that are less toxic and more effective for Merkel Cell Carcinoma (MCC). On noting that MCC cases have increased by 95% from 2010 to 2017, Dr. Nghiem addressed three main goals that aim to improve patient care. Preliminary studies highlight that performing wide local excisions pose the risk of increased morbidity and delayed time to radiation treatment. Additionally, patients treated with immunotherapy have shown higher overall survival rates and recurrence free survival in comparison to patients treated with traditional chemotherapy. To implement customized care, a dedicated team of physicians across multiple specialties are best guided by an overseeing dermatologist.
To read more, click here to view the article.Download the article
The authoritative source on Merkel cell carcinoma.
March 21, 2019